



Virazole® (ribavirin) – First-Time Generic

- Zydus Pharmaceuticals announced the upcoming launch of Navinta's [AN-rated](#) generic version of Valeant's [Virazole \(ribavirin\)](#) vials for inhalation.
 - Zydus plans to launch Navinta's generic Virazole by the end of January 2017.
- Virazole is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus.
- Virazole carries boxed warnings for the following:
 - Use of aerosolized Virazole in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with the specific ventilator being used and this mode of administration of the drug.
 - Sudden deterioration of respiratory function has been associated with initiation of aerosolized Virazole use in infants.
 - Virazole is not indicated for use in adults.
 - Physicians and patients should be aware that ribavirin has been shown to produce testicular lesions in rodents and to be teratogenic in all animal species in which adequate studies have been conducted.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.